Patents by Inventor Sarah Beth Hesse

Sarah Beth Hesse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Immunotherapy
    Publication number: 20210340530
    Abstract: Compositions and methods for editing, e.g., altering a DNA sequence, within the TRBC1, TRBC2 and/or TRAC genes are provided. Compositions and methods for immunotherapy are provided, for example.
    Type: Application
    Filed: April 15, 2021
    Publication date: November 4, 2021
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Amy Melissa Becker, Surbhi Goel, Sarah Beth Hesse, Troy Aaron Luster, Birgit Schultes, Stephanie A. Yazinski, Pooja Vinay
  • Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)
    Publication number: 20210163943
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the HAO1 gene are provided. Compositions and methods for treating subjects having primary hyperoxaluria type 1 (PH1), are provided.
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Zachary William Dymek, Shobu Odate, Bradley Andrew Murray, Reynald Michael Lescarbeau, Anette Huebner, Walter Strapps, Sarah Beth Hesse
  • Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four
    Publication number: 20190142972
    Abstract: This application relates to compositions and methods for excising trinucleotide repeats (TNRs) contained within intron 3 of TCF4, such as is seen in subjects having Fuchs endothelial corneal dystrophy (FECD), PSC, and Schizophrenia. Compositions comprising guide sequences targeting the alpha 2 subunit of collagen VIII are also disclosed for treatment of mutations therein that may contribute to FECD.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 16, 2019
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Sean Michael Burns, Bradley Andrew Murray, Sarah Beth Hesse